April 2013. The Native Antigen Company (NAC); http://thenativeantigencompany.com announces the release of highly purified toxins and toxoids of Clostridium difficile ribotypes 027 and 078 for use in research, vaccine development and by IVD manufacturers.
Clostridium difficile infection (CDI) is a major cause of morbidity and mortality in economically developed countries. CDI is primarily linked with hospital admission and prior antimicrobial treatment. Although significant advances have been made to reduce incidence, a number of hypervirulent and highly transmissible strains have recently emerged. Resultant healthcare challenges are compounded as widespread use of antibiotics encourages both the emergence of resistant strains and reoccurrence of infection, especially in the elderly.
The availability of these cost effective, high performance toxins and toxoids is timely and supports the increasing healthcare focus on combating these hypervirulent strains.
To satisfy a broad range of applications, the products are offered as separate preparations in a variety of vial sizes and are suitable for long term storage,
For more information please contact Andrew Maxwell, CEO Native Antigen Company +44 (0) 1869 238067, email@example.com
or visit www.thenativeantigencompany.com